Literature DB >> 24397093

Maternal and foetal outcome in HELLP syndrome at tertiary care hospital.

Nigar Sadaf1, Gulfishan Haq1, Shazia Shukar-ud-Din1.   

Abstract

OBJECTIVE: To determine maternal and foetal outcome in patients of Haemolysis, Elevated Liver enzyme and Low Platelet Cont syndrome.
METHODS: The descriptive case series was conducted at the Gynae Unit II of Civil Hospital, Karachi, over a period of 12 months in two episodes; first from December 28, 2006, to February 28, 2007, and then from September 1, 2007, to June 30, 2008. It comprised 40 consecutive women with pre-ecampsia and eclampsia along with altered platelet count who met the syndrome criteria. A pre-designed proforma was administered for data collection. Maternal and foetal outcomes were noted. SPSS 10 was used for statistical analysis. RESULT: Among the 40 mothers, cesarean section was the most common outcome (n=24; 60%). Pulmonary oedema was found in 2 (5%) cases, acute renal failure in 10 (25%), disseminated intravascular coagulation in 6 (15%), and abruptio placenta in 5 (12.5%). Intrauterine growth restriction as a foetal outcome was observed in 18 (45%) cases. Pre-term birth was the result in 20 (50%) cases, and perinatal mortality was high (n=23; 57.5%).
CONCLUSION: Management and delivery of HELLP syndrome patients should be performed at tertiary care centres, where highly trained obstetrician, neonatal intensive care unit personnel and Multi-disciplinary facilities are available. Correct diagnosis and timely intervention can decrease the risk of maternal and perinatal mortality.

Entities:  

Mesh:

Year:  2013        PMID: 24397093

Source DB:  PubMed          Journal:  J Pak Med Assoc        ISSN: 0030-9982            Impact factor:   0.781


  1 in total

1.  Prevalence of Hemolysis, Elevated Liver Enzymes, Low Platelet Count Syndrome in Pregnant Women in a Tertiary Care Hospital.

Authors:  Sarita Sitaula; Tara Manandhar; Baburam Dixit Thapa; Ramesh Shrestha; Dinesh Dharel
Journal:  JNMA J Nepal Med Assoc       Date:  2020-06-30       Impact factor: 0.406

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.